CEO James Foster on Virax Biolabs' (VRAX) Long COVID Diagnostic & US Market Entry
May. 14, 2026
n our investor-focused interview, James Foster, CEO of Virax Biolabs Group Ltd. (Nasdaq: VRAX), breaks down how the company is developing a potential first-in-category immune function diagnostic targeting post-acute infection syndromes (PAIS) — a large, underserved category affecting an estimated 21 million people in the U.S. with no widely adopted objective diagnostic test.
Virax's lead product, ViraxImmune™, is designed to move beyond static blood markers and deliver objective immune dysfunction profiling for conditions including Long COVID, ME/CFS, and post-treatment Lyme disease which collectively represent an economic burden exceeding $25 billion annually in the U.S.
James walks investors through the company's planned U.S. market entry via the laboratory-developed test (LDT) pathway, its clinical validation milestones underway in 2026, a near-term data readout, and the path toward a targeted 2027 commercial launch — all supported by a strengthened balance sheet of approximately $6.4M in cash and no debt.
